Our laboratory offers both IgG antibody and molecular testing for the detection of coronavirus (SARS-CoV-2).

Molecular testing is performed on fluids from nasopharyngeal and nasal specimens. This real-time RT-PCR diagnostic panel is intended for diagnostic testing in symptomatic patients, suspected of exposure to COVID, or screening for exposure to asymptomatic individuals for COVID. The clinical criteria for testing using this panel includes those with clinical symptoms of COVID-19 and individuals know to have been in contact with a confirmed case of COVID-19. It is unknown when viral levels are at peak during an active infection, therefore, multiple samples may be required to detect the virus. More information about the appropriate use of testing can be found here: CDC Testing Guidance

Antibody testing against SARS-CoV-2 is performed on serum usually after a patients has recovered from COVID-19 or a minimum of 10 days after initial exposure. This test is not used to confirm a clinical diagnosis. Having detectable antibodies to SARS-CoV-2 may mean a patient has some immunity, however, the World Health Organization states that having antibodies does not mean patients are completely protected from reinfection. Our analysis is performed on the Architect i1000sr instrument which utilizes chemiluminescent microparticle immunoassay technology (CMIA), providing results 24-48 hours after receipt of sample.